Abstract
Background
Burn injuries cause severe physical and psychological challenges. Current treatments have limitations, such as incomplete skin regeneration and prolonged healing times, necessitating innovative solutions. Tissue engineering integrates mesenchymal stem cells (MSCs) and scaffolds in preclinical studies to enhance healing, reduce scarring, and regenerate skin. This study examines their combined effects to optimize burn wound therapies.
Methods
This systematic review and meta-analysis was conducted per PRISMA guidelines, with the protocol registered in PROSPERO. Databases (PubMed, Embase, Scopus, Web of Science, ProQuest) were searched for published studies.The SYRCLE tool assessed risk of bias. Standardized mean difference (SMD) evaluated the therapeutic effect of MSC-scaffold combinations. Statistical analysis employed a random-effects model. Sensitivity analysis, publication bias assessment, and subgroup analysis addressed heterogeneity.
Results
Our meta-analysis reveals that animals treated with MSC-scaffold combinations exhibit enhanced wound closure compared to untreated controls across short-term (SMD = 3.97), mid-term (SMD = 3.47), and long-term (SMD = 3.03) timeframes. Additionally, MSC-scaffold combinations significantly improve angiogenesis (SMD = 6.24), collagen deposition (SMD = 4.97), and growth factor expression (SMD = 6.68), while effectively modulating inflammatory cytokine levels (SMD = -4.88).
Conclusion
Our research demonstrates that MSC-scaffold synergy in preclinical burn wound healing significantly improves wound closure, collagen deposition, angiogenesis, and growth factor expression, while effectively modulating inflammatory responses. Despite its potential as an adjunctive therapy, substantial study heterogeneity impedes clinical translation, necessitating standardized protocols to refine and validate this approach for efficacious clinical application.
Graphical Abstract
Supplementary Information
The online version contains supplementary material available at 10.1186/s12967-025-06712-y.
Keywords: Mesenchymal stem cells, Exosome, Scaffold, Matrix, Hydrogel, Burn, Cell therapy
Introduction
The skin, the body’s largest organ, serves as a critical barrier against environmental threats [1]. Burn injuries impair this protective function, posing significant psychological and physiological challenges [2]. Beyond causing physical pain and functional loss, burns often result in long-term psychological distress, reducing quality of life [3, 4]. Globally, burn injuries remain a major public health concern, claiming numerous lives annually and leaving survivors with debilitating impairments [5]. Severe burns extend beyond superficial tissue damage, triggering systemic complications such as hypovolemic shock, immune dysfunction, and metabolic disturbances, which complicate treatment and recovery. Burn wound healing is a complex, dynamic process involving inflammatory, proliferative, and remodeling phases [2]. However, the extent and depth of thermal damage can prolong and disrupt this process. Complications like infections, excessive scarring, and contractures hinder functional recovery if not addressed promptly and effectively [6]. Despite advances in clinical care—such as early excision of necrotic tissue, skin grafting, and skin substitutes—current treatments face limitations, including donor site shortages, graft rejection, infection risks, and suboptimal aesthetic and functional outcomes [7–9]. Consequently, innovative therapies are urgently needed to accelerate healing, promote skin regeneration, and minimize long-term complications. Tissue engineering, integrating biomaterials, cellular therapies, and bioactive compounds, offers promising solutions by developing functional skin substitutes to enhance wound healing [10–12]. Engineered skin substitutes show potential in closing wounds, reducing scarring, and restoring skin integrity [13]. Advanced biofabrication techniques, such as 3D bioprinting, have revolutionized the design of bioengineered skin by enabling precise spatial arrangement of cells and extracellular matrix components [14]. Biomaterials like silk fibroin and polymeric hydrogel scaffolds have been extensively studied for their ability to support skin regeneration [15, 16]. These materials promote angiogenesis, re-epithelialization, and biocompatibility, minimizing adverse immune responses [17, 18]. Scaffolds play a pivotal role in tissue engineering by providing structural support and an optimal environment for cellular adhesion, proliferation, and differentiation. Among scaffold materials, hydrogels stand out due to their high water content, biocompatibility, and ability to mimic the natural extracellular matrix [19, 20]. Bioactive compounds—such as polyethylene glycol, sodium alginate-collagen hydrogel, and chitosan-based materials—enhance scaffold performance by modulating cellular activity and promoting tissue regeneration [20, 21]. These scaffolds not only support implanted cells but also regulate the wound microenvironment and enable controlled release of therapeutic agents, accelerating healing. Mesenchymal stem cells (MSCs) have gained attention in regenerative medicine for their immunomodulatory properties, multipotency, and ability to secrete paracrine factors that enhance tissue repair [22]. MSCs reduce inflammation, promote angiogenesis, and support the formation of new skin structures [23]. A pivotal element in the therapeutic efficacy of MSCs is their secretome, a complex repertoire of bioactive molecules secreted by these cells [24]. The MSC secretome comprises various growth factors—such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF)—as well as cytokines and extracellular vesicles, all of which collectively orchestrate the wound healing process [25]. These secreted factors exert paracrine effects that enhance angiogenesis, promote cellular proliferation and migration, modulate inflammation, and facilitate extracellular matrix remodeling—processes that are crucial for effective healing of burn wounds [26]. Recent studies have demonstrated that the application of the MSC secretome can accelerate wound closure and improve healing outcomes in preclinical models of burn injury [27]. Moreover, the use of the MSC secretome offers distinct advantages over cell-based therapies, including reduced risks of immune rejection and tumorigenicity, along with the potential for the development of standardized, off-the-shelf therapeutic products [28].However, the harsh burn wound environment can limit MSC survival and efficacy, reducing their therapeutic potential [15]. To address this, researchers have explored integrating MSCs into scaffolds and hydrogels, providing a protective niche that enhances MSC survival, proliferation, and regenerative effects. For instance, Alapure et al. demonstrated in a mouse model that bone marrow-derived MSCs embedded in a biodegradable hydrogel scaffold significantly improved burn wound healing, highlighting the synergistic potential of combining biomaterials with MSC therapy [29]. Integrating stem cells’ regenerative capabilities with the structural and biochemical support of biomaterials represents a promising advancement in burn wound treatment [30, 31]. Despite growing interest, significant knowledge gaps persist regarding the mechanisms underlying their combined effects and optimal conditions for clinical translation. While prior studies have explored various aspects of tissue engineering for burns—including biomaterials and stem cell therapies—a comprehensive systematic review and meta-analysis focusing on the combined impact of MSCs and scaffolds remains absent. This work aims to fill this gap by systematically evaluating preclinical data, providing novel insights into optimal combinations of stem cells, scaffolds, and therapeutic strategies. By synthesizing existing findings, this review seeks to inform future research directions and facilitate the development of an effective, clinically translatable MSC-based therapy for burn wound management, ultimately improving patient outcomes.
Methods
Protocol and registration
The protocol for this systematic review and meta-analysis was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration code CRD420251004458 on [4 March 2025]. The PRISMA 2020 checklist was rigorously followed to ensure transparent and comprehensive reporting of the methodology and findings of this study [32].
Eligibility criteria
To establish eligibility criteria for study inclusion, we adopted the widely recognized PICOS framework, which organizes the evaluation process around five key components: Population, Intervention, Comparator, Outcomes, and Study Design [33]. This standardized approach ensures objectivity, reproducibility, and transparency in the analysis, facilitating the systematic identification, inclusion, and unbiased assessment of relevant studies. Below, we outline the inclusion and exclusion criteria for the studies, structured according to the five core elements of the PICOS framework.
Population
The study population included all mammalian species, excluding humans, in which burn injury models were applied, regardless of age or gender. Studies focusing on non-mammalian species or those conducted exclusively in laboratory settings (in vitro) were excluded. Additionally, any studies involving wound creation methods other than burn injuries were also excluded.
Intervention
The primary intervention for study inclusion was the direct administration of MSCs combined with scaffolds or MSC-derived secretomes with scaffolds. There were no restrictions on dosage, administration route, or timing of intervention. Studies investigating the therapeutic effects of cell types other than MSCs were excluded. Similarly, studies utilizing MSCs alone, MSC secretomes alone, or scaffolds alone were excluded. The use of scaffolds with dual cellular layers was also considered an exclusion criterion.
Comparator
The selected comparator group consisted of animals subjected to burn injuries but receiving no treatment.
Outcomes
The primary outcome of interest was wound closure, as reported in the studies or extracted from graphical data. Secondary outcomes included assessments of angiogenesis, collagen levels, inflammatory cytokine levels, and growth factor levels. Studies were required to report primary outcomes to be included; those lacking primary outcome data were excluded.
Study design
All included studies were controlled interventional trials, either randomized or non-randomized, that compared the synergistic effects of MSCs and scaffolds against placebo or a"no treatment"control in animal burn models. Excluded studies comprised editorials, review articles, theoretical papers, narrative reviews, systematic reviews, letters to the editor, and conference abstracts to ensure the inclusion of only original and methodologically rigorous research.
Information sources and search strategy
A systematic search was conducted across multiple databases, including PubMed, Embase, Web of Science, Scopus, and ProQuest, covering the period from January 1, 1994, to November 30, 2024. In addition to the database searches, the reference lists of relevant studies were manually examined to identify any potentially overlooked studies that might not have been captured during the initial database searches. The search strategies were tailored for each database, incorporating controlled vocabulary terms such as MeSH (Medical Subject Headings) and other relevant keywords. Input from domain experts was also sought to ensure the inclusion of critical keywords and abbreviations. Detailed search strategies are provided in (Supplementary Data S1, Tables 1, 2, 3, 4 and 5).
Table 1.
Summary of key characteristics of animal models in included studies
| References | Animal model | Animal strain | Gender/age | Number of animals in case & control groups | Model of burn | Burn wound creation method |
|---|---|---|---|---|---|---|
| Alapure [29] | Mouse | C57BL/6J | Female/9 weeks | 4 & 4 | 3o Burn | 100 °C aluminum rod for 4 S |
| AV [42] | Rat | Wistar | Male/8–weeks | 3 & 3 | 2o Burn | 120 ± 5 °C metallic punch for 20 S |
| Banerjee [43] | Rat | Wistar | Male/8 weeks | 4 & 4 | NA | 87 °C brass disk for 10 S |
| Barrera [44] | Mouse | C57BL/6J | NA/8–12 weeks | 4 & 4 | 2o Burn | 100 °C aluminum cylinder for 15 S |
| Cabello-Arista [45] | Mouse | Athymic | Male/12 weeks | 5 & 5 | 3o Burn | 105 °C copper device for 5 S |
| Fang [46] | Mouse | C57BL/6J | Male/NA | 6 & 6 | 3o Burn | 15 Gy X-ray irradiation for 3 sessions |
| Ghaneialvar [47] | Rat | NA | NA/NA | 3 & 3 | NA | 100 °C 1 × 1 cm2 plate |
| Gholipour [48] | Rat | Sprague Dawley | Male/adult | 3 & 3 | 3o Burn | 150 °C brass probe for 60 S |
| Guo [49] | Rat | Sprague Dawley | Male/adults | 4 & 4 | 3o Burn | 100 °C glass pipe for 10 S |
| Liu [50] | Pig | Yorkshire | NA | 6 & 6 |
2o Burn Deep partial thickness |
100 °C brass block for 20 S |
| Lu [51] | Rat | Wistar | Male/8 weeks | 4 & 4 | 2o Burn | 100 °C stainless-steel cylinder for 15 S |
| Lu [52] | Mouse | C57BL/6J | Female/5–10 month | 3 & 3 | 3o Burn | 110 °C brass rods for 40 S |
| Motamed [53] | Rat | Sprague Dawley | Male/NA | 8 & 8 | 3o Burn | 100 °C bar for 30 S |
| Naasani [54] | Rat | Wistar | Female and male/8 weeks | 5 & 5 |
2o Burn Deep partial thickness |
70 °C aluminum cylindrical head for 10 S |
| Ng [55] | Mouse | C57BL/6ntac | Female/6–8 weeks | 3 & 3 | 3o Burn | 100 °C stainless-steel bar for 30 S |
| Paramasiva [56] | Rat | Wistar | Male/NA | 15 & 15 | 3° Burn | 130 °C steel bar for 30 S |
| Peng [27] | Mouse | C57BL/6J | Male/6 weeks | 3 & 3 | 3° Burn | 5 Gy γ-radiation for 2 H |
| Rasouli [57] | Rat | Wistar | Male/adult | 3 & 3 | 3° Burn | 100 °C brass rod for 30 S |
| Shahmohammadi [58] | Rat | Wistar | Male/NA | 3 & 3 | 2o Burn | 100 °C metal disk for 10 S |
| Yingwei Wang [60] | Rabbits | New Zealand | Male/12 weeks | 4 & 4 | 3° Burn | 100 °C metal block for 15 S |
| Shihan Wang [59] | Mouse | C57 | Female/6–8 weeks | 7 & 7 |
2o Burn Deep partial thickness |
NA |
| Wu [61] | Mouse | Balb/C | Male/8 weeks | 8 & 8 | 3° Burn | 100 °C steel bar for 60 S |
| Yang [62] | Mouse | C57BL/6J | Female/6–8 weeks | 8 & 8 |
2o Burn Deep partial thickness |
NA |
| Yao [63] | Mouse | C57BL/6J | Female/6–8 weeks | 8 & 8 | 3° Burn | 10 Gy X-ray exposure for 3 days |
| Panpan Zhou [64] | Mouse | C57BL/6J | Male/6 weeks | 18 & 18 | 3° Burn | 95 °C iron mold for 10 S |
| Zixuan Zhou [65] | Mouse | C57BL/6J | NA/6–weeks | 10 & 10 |
2o Burn Deep partial thickness |
100 °C copper rod for 5 S |
| Zhu [66] | Mouse | Balb/C | Male/8 weeks | 5 & 5 | 3° Burn | 100 °C iron rod for 30 S |
Table 2.
Overview of MSC Characteristics in Included Studies
| Refs. | Type of MSCs | Source of MSCs | Characterization Based on ISCT | |
|---|---|---|---|---|
| Immunophenotyping | Differentiation | |||
| Alapure [29] | Bone Marrow | Mouse | Sca-1+/CD29+ | Adipogenic/chondrogenic |
| AV [42] | Bone Marrow | Human |
CD29+/CD105+/CD73+/CD90+/HLA-I+ AND CD34−/CD35−/HLA-II− |
Adipogenic/chondrogenic/osteogenic |
| Banerjee [43] | Adipose | Rat |
CD29+/CD44+/CD71+/CD90+/CD105+ AND CD31−/CD34−/CD45− |
Chondrogenic/osteogenic |
| Barrera [44] | Adipose | Mouse | NA | NA |
| Cabello-Arista [45] | Adipose | Human |
CD90+/CD73+/CD44+/CD105+ AND HLA-DR−/CD45−/CD34− |
NA |
| Ghaneialvar [47] | Bone Marrow | Rat |
CD90+/CD73+/CD105+ AND CD45−/CD34−/CD14− |
Adipogenic/osteogenic |
| Gholipour [48] | Umbilical Cord | Human |
CD29+/CD105+/CD44+/CD51+ AND CD45−/CD34− |
Adipogenic/chondrogenic/osteogenic |
| Guo [49] | Bone Marrow | Rat | NA | NA |
| Liu [50] | Bone Marrow | Pig | CD44+/CD90+ | NA |
| Lu [51] | Adipose | Human | NA | Adipogenic/chondrogenic/osteogenic |
| Lu [52] | Adipose | Mouse | NA | NA |
| Motamed [53] | Adipose | Human |
CD44+/CD90+/CD105+ AND CD31−/CD34−/CD45− |
Adipogenic/chondrogenic/osteogenic |
| Naasani [54] | Adipose | Rat |
CD29+/CD90+/CD73+ AND CD45− |
Adipogenic/chondrogenic/osteogenic |
| Ng [55] | Adipose | Human | NA | NA |
| Paramasiva [56] | Bone Marrow | Rat |
CD29+/CD90+ AND CD45−/CD31− |
Adipogenic/chondrogenic/osteogenic |
| Rasouli [57] | Adipose | Human |
CD90+/CD73+/CD105+ AND CD45−/CD34−/CD14−/CD20− |
Adipogenic/osteogenic |
| Shahmohammadi [58] | Adipose | Rat |
CD73+/CD90+/CD105+ AND CD34−/CD45− |
Adipogenic/chondrogenic/osteogenic |
| Shihan Wang [59] | Umbilical Cord | Human | NA | NA |
| Wu [61] | Adipose | Mice |
CD73+/CD90+/CD105+ AND CD34−/CD45−/HLA-DR− |
Adipogenic/chondrogenic/osteogenic |
| Zixuan Zhou [65] | Umbilical Cord | Human | NA | NA |
Table 3.
Overview of MSC-secretome characteristics in included studies
| Refs. | Type of human MSCs | Type of secretome | Isolation methods | Characterization | ||
|---|---|---|---|---|---|---|
| Morphology | Particle number and size | Surface Markers | ||||
| Fang [46] | Umbilical Cord | Small extracellular vesicles | Ultrafiltration | Transmission electron microscope | Nanoparticle tracking analysis | CD9/CD63/CD81/Calnexin |
| Peng [27] | iPSC-derived MSCs | Exosome | Ultracentrifugation | Transmission electron microscope | Nanoparticle tracking analysis | CD9/CD63/TSG101/HSP70 |
| Yang [62] | Umbilical Cord | Exosome | Ultrafiltration | Transmission electron microscope | Nanoparticle tracking analysis | CD63/Flotillin-1/Calnexin |
| Yao [63] | Adipose | Microvesicles | Ultracentrifugation | Transmission electron microscope | Nanoparticle tracking analysis | CD9/TSG101/Tom20 |
| Zhu [66] | Adipose | Exosome | Ultracentrifugation | Transmission electron microscope | Nanoparticle tracking analysis | CD81/TSG101 |
| Yingwei Wang [60] | Umbilical Cord | Paracrine proteins | Ultrafiltration | Mass spectrometric analysis | ||
| Panpan Zhou [64] | Umbilical Cord | Conditioned medium | Ultrafiltration | |||
Table 4.
Overview of scaffold characteristics in included studies
| Polymer-based scaffold | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Refs. | Scaffold compositions/form/characterization | Structural properties | Biological properties | |||||||
| Composition | Form | Characterization | Morphology | Physico-chemical | Mechanical | Bio-compatibility | Cell adhesion | Cell proliferation | Cell migration | |
| Alapure [29] | Unsaturated Arginine Polyesteramine + Glycidyl methacrylate chitosan | Injectable hydrogel |
SEM1 DMA2 Zeta potential Swelling Kinetics Degradation analysis In vitro Live/dead and Cell adhesion assay |
Pore size: 50 μm |
Swelling ratio: 1670% at 16 h Degradation: 50% in 10 days |
Compressive modulus: 17.8 KP | In vitro Good cell viability | Good | NA | NA |
| AV [42] | Gelatin + Hyaluronic Acid + Chondroitin Sulfate | Foam |
SEM ATR-FTIR3 DSC4 TGA5 Mechanical Properties In vitro LDH Cytotoxicity and in vivo Blood Biochemistry and Histopathology assay |
Pore size: 70 −100 μm |
Swelling ratio: 620% at 24 h Degradation: 100% in 12 days |
Tensile strength 0.0689 + 0.13 MPa | In vitro and in vivo Good Bio-Compatibility | NA | NA | NA |
| Banerjee [43] | PEGylated fibrin + Silver sulfadiazine-loaded chitosan Microsperes | Amorphous hydrogel |
SEM Rheological analysis Swelling Kinetics Degradation Test Mechanical Test MTT |
Fiber diameter: less than 200 μm |
Swelling ratio: 100% at 24 h Degradation: 100% in Less than 60 min |
Compressive modulus: 200 Pa | In vitro Good cell viability | In vitro Good cell Adhesion | NA | NA |
|
Barrera [44] |
Pullulan + Collagen | Film hydrogel |
SEM NEA6 Swelling Kinetics Degradation Test In vitro Live/dead and Cell adhesion and cell migration assay |
Pore size: 34.15 μm Porosity: 74.8% |
Swelling ratio:333% at 24 h Degradation: 100% in 72h |
NA | In vitro Good cell viability | In vitro Good cell Adhesion | - | In vitro Good cell Migration |
| Fang [46] | carbohydrazide-modified gelatin + oxidized hyaluronic acid + Polydopamine nanoparticles | Freeze-dried hydrogel |
SEM FTIR Swelling Kinetics UV–vis Spectrophotometry Swelling Kinetics Rheological analysis H NMR7 Mechanical Test Degradation Test In vitro Live/dead and CCK-8 assay Histopathology assay |
NA |
Swelling ratio 106% to 117% at 3 h Degradation: 100% in 96 h |
Compressive modulus: 1000 Pa | In vitro and in vivo Good Bio-Compatibility | NA | In vitro Good cell Proliferation | NA |
| Ghaneialvar [47] | Docosahexaenoic Acid + Chitosan + Alginate | Film hydrogel |
SEM FTIR XRD8 In vitro Live/dead assay |
Pore size: 30–100 μm Porosity: 85 to 95% |
NA | NA | In vitro Good cell viability | NA | NA | NA |
| Gholipour [48] | Polycaprolactone + Chitosan + Polyvinyl Alcohol | Nanofiber hydrogel |
SEM FTIR DSC MTS |
Fiber diameter:136 μm | NA | NA | In vitro Good cell viability | NA | NA | NA |
| Liu [50] | Collagen + Glycosaminoglycans | Freeze-dried hydrogel | NA | NA | NA | NA | In vitro Good cell viability | NA | NA | NA |
| Lu [51] | Gelatin | Injectable hydrogel |
SEM DMA Degradation Test In vitro Live/dead and cell adhesion and cell proliferation assay |
Pore size: 150–250 mm | Degradation: 100% in 8h | Compressive modulus: 15 KP | In vitro Good cell viability | In vitro Good cell Adhesion | In vitro Good cell Proliferation | NA |
| Lu [52] | Unsaturated Arginine Polyesteramine + Glycidyl methacrylate chitosan + pro-regenerative lipid mediator 1 | Injectable hydrogel |
SEM DMA Swelling Kinetics Zeta potential Analysis Degradation Test In vitro Live/dead and cell adhesion assay |
Pore size: 50 μm |
Swelling ratio: 1670% at 16 h Degradation: 50% in 10 days |
Compressive modulus: 17.8 KP | In vitro Good cell viability | In vitro Good cell Adhesion | NA | NA |
| Ng [55] | Gellan Gum + Collagen | Injectable hydrogel |
SEM Rheological analysis Swelling Kinetics Degradation Test Mechanical Test MTS In vitro cell proliferation and cell migration assay |
Pore size: ∼150 μm |
Swelling ratio: 157.9% at 24 h Degradation: 100% in 21 days |
Compressive modulus: 2.35 KP | In vitro Good cell viability | NA | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Peng [27] |
Oxidized Sodium Alginate Quaternized Chitosan |
Injectable hydrogel |
SEM FTIR Swelling Kinetics Rheological analysis NMR Lap shear test In vitro Live/dead and CCK-8 and cell migration assay |
NA | NA | Compressive modulus: 131 kPa | In vitro and in vivo Good Bio-Compatibility | NA | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Rasouli [57] | Carboxylated Cellulose + palmitoyl Pentapeptide-4 | Film hydrogel |
SEM MTT In vitro cell proliferation assay |
Pore size: 0.783 ± 0.32 μm | NA | NA | In vitro Good cell viability | In vitro Good cell Adhesion | NA | NA |
| Shahmohammadi [58] | Polycaprolactone + Gelatin + MnO2 nanoparticles | Nanofiber hydrogel |
SEM FT-IR Contact angle Swelling Kinetics Tensile Properties Degradation Test MTT In vitro cell adhesion assay |
Fiber diameter: 548.838 μm Porosity: 90 to 95% |
Swelling ratio:400% at 24h Degradation: 10% in 21 days |
Tensile strength: 2 to 2.5Mpa |
In vitro and in vivo Good Bio-Compatibility | In vitro Good cell Adhesion | NA | NA |
| Yingwei Wang [60] | Gelatin + Hyaluronic Acid | Injectable hydrogel |
SEM FITR Rheological analysis Mechanical Test In vitro Live/dead and cell adhesion and CCK-8 and cell migration assay |
NA | NA | Compressive modulus: 1 Pa | In vitro Good cell viability | In vitro Good cell Adhesion | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Shihan Wang [59] | Hyaluronic Acid + adipic acid dihydrazide + Dopamine nanoparticles | Freeze-dried hydrogel |
SEM FITR Rheological analysis Swelling Kinetics Degradation Test Mechanical Test In vitro Live/dead and cell adhesion and CCK-8 and cell migration assay |
Pore size: ∼38 to 50 μm |
Swelling ratio: 800% at 30 h Degradation: 100% in 14 days |
Compression stress–strain: 45 Kpa |
In vitro Good cell viability | In vitro Good cell Adhesion | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Wu [61] | Alginate + Gelatine + S-Nitroso-N-acetyl-D, L-penicillamine | Bioprinted hydrogel |
SEM In vitro Live/dead and cell adhesion and cell proliferation and cell migration assay |
NA | NA | NA | In vitro Good cell viability | In vitro Good cell Adhesion | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Yang [62] | Hyaluronic Acid/PolyDopamine/Maltooligosaccharide | Freeze-dried hydrogel |
SEM FTIR Rheological analysis In vitro Live/dead and CCK-8 and cell migration assay |
NA | NA | Compressive modulus: 15 kpa | In vitro Good cell viability | NA | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Yao [63] | Decellularized Adipose Matrix/hyaluronic Acid Methacrylic Acid | Injectable hydrogel |
SEM DAM Degradation Test In vitro Live/dead and CCK-8 assay |
Pore size: 168.96 μm | Degradation: 80% in 12 days | Young’s modulus: 1.75 Mpa | In vitro Good cell viability | NA | In vitro Good cell Proliferation | NA |
| Panpan Zhou [64] | hyaluronic Acid/chitosan/Collagen | Injectable hydrogel |
Viscosity testing CCK-8 assay |
NA | NA | Viscosity: 650–750 mPa·s | In vitro Good cell viability | NA | NA | NA |
| Zhu [66] | hyaluronic acid | Injectable hydrogel |
SEM Viscosity testing |
NA | NA |
Compression strain: 2–2.5 pa |
NA | NA | NA | NA |
| Biological-based scaffold | ||||||||
|---|---|---|---|---|---|---|---|---|
| Ref | Source of matrix | Tissue | Decellularization methods | Confirmation of decellularization | Biological properties | |||
| Bio-compatibility | Cell adhesion | Cell proliferation | Cell migration | |||||
| Cabello-Arista [45] | Human and Animal |
Human Amnion Membrane Pig Skin |
NA | NA | In vitro Good cell viability | NA | In vitro Good cell Proliferation | In vitro Good cell Migration |
| Guo [49] | Animal | Pig Small Intestinal Submucosa |
Physico/chemical Combination method by Mechanical removal method and Trypsin + Sodium Dodecylsulphate |
SEM/Amount of DNA/Histological analysis by H&E | In vitro Good cell viability | In vitro Good cell Adhesion | NA | NA |
| Motamed [53] | Human |
Human Amnion Membrane |
Physico/chemical Combination method by cell scraper and Trypsin–EDTA | DAPI staining | In vitro Good cell viability | In vitro Good cell Adhesion | NA | NA |
| Naasani [54] | Human |
Human Amnion Membrane |
Chemical method by Trypsin–EDTA | NA | In vitro Good cell viability | NA | NA | NA |
| Paramasiva [56] | Animal | Pig Urinary Bladder | Chemical method by Sodium dodecyl sulfate/Dnase/Rnase | Histological analysis by H&E and Masson’s trichrome staining/Amount of DNA | NA | NA | NA | NA |
| Zixuan Zhou [65] | Human |
Human Amnion Membrane |
Physico/chemical Combination method by Freeze–thaw cycles and Dnase |
DAPI staining | In vitro Good cell viability | In vitro Good cell Adhesion | In vitro Good cell Proliferation | NA |
1. Scanning Electron Microscope, 2. Dynamic Mechanical Analyzer, 3. Attenuated Total Reflection Fourier Transform Infrared Analysis, 4. Differential Scanning Calorimetry, 5. ThermoGravimetric analysis, 6. Network Extraction Analysis, 7. Proton Nuclear Magnetic Resonance, 8. X-ray diffraction
Table 5.
Subgroup analysis results of included studies
| Subgroup Analysis | Time frame | ||
|---|---|---|---|
| 1 Week SMD (95% CI) I2% |
2 Week SMD (95% CI) I2% |
3 Week SMD (95% CI) I2% |
|
| Cell or Secretome | |||
| Cell |
4.75 (3.15–6.36) 62.6% |
3.20 (1.71–4.68) 81.1% |
2.29 (1.68–4.31) 71.9% |
| Secretome |
2.90 (1.77–4.03) 37.4% |
3.94 (2.30–5.58) 71.4% |
3.25 (1.89–4.61) 0% |
| Sample size | |||
| Low |
3.09 (1.80–4.39) 56% |
3.22 (1.59–4.85) 66.2% |
2.25 (0.81–3.69) 56.9% |
| Sufficient |
4.90 (3.10–6.69) 78.5% |
3.79 (1.72–5.86) 86.6% |
4.06 (1.78–6.34) 70.6% |
| High |
3.73 (− 1.57–9.03) 96.3% |
3.19 (1.63–4.76) 76.3% |
3.77 (2.52–5.01) |
| Risk of bias | |||
| Low |
3.65 (2.67–4.62) 76.2% |
3.48 (2.14–4.83) 80.5% |
2.95 (2.03–3.88) 37.1% |
| Unclear |
4.84 (1.92–7.77) 87% |
3.55 (1.13–5.97) 79% |
3.06 (0.99–5.14) 80.2% |
| Cell | |||
| Type of animal | |||
| Mouse |
3.83 (1.96–5.69) 65.2% |
3.43 (− 0.47–7.33) 90.9% |
– |
| Rat |
5.60 (2.48–8.71) 85.9% |
2.09 (0.93–3.26) 66.2% |
2.28 (1.16–3.41) 64.1% |
| Rabbit | 7.70 (4.21–11.18) | 5.36 (2.82–7.91) | 4.62 (2.36–6.87) |
| Pig | – | 6.46 (3.15–9.77) | 9.32 (4.69–13.95) |
| Model of burn | |||
| Second-degree |
3.95 (2.00–5.90) 81.3% |
3.49 (1.41–5.56) 84.6% |
3.21 (0.99–5.43) 78.9% |
| Third-degree |
6.36 (2.99–9.74) 81.2% |
2.46 (0.31–4.60) 80.1% |
2.83 (1.64–4.01) 41% |
| Type of scaffold | |||
| Hydrogel |
4.02 (2.37–5.67) 77.7% |
3.41 (1.89–4.93) 72.4% |
3.60 (1.31–5.89) 77.5% |
| Biological scaffold |
8.83 (0.76–16.90) 83.8% |
2.75 (− 0.54–6.04) 88.8% |
2.74 (1.56–3.91) 49.4% |
| Type of MSCs | |||
| Bone Marrow |
6.27 (4.74–7.81) 0.0% |
4.27 (1.73–6.81) 59.9% |
4.42 (1.83–7.02) 64.9% |
| Adipose |
4.16 (1.27–7.05) 78.1% |
1.56 (0.01–3.10) 79.3% |
1.51 (− 0.28–3.30) 62.9% |
| Umbilical Cord |
6.74 (4.88–8.60) 0.0% |
6.30 (4.03–8.56) 31.6% |
3.29 (0.64–5.94) 61.9% |
| Source of MSCs | |||
| Allograft |
3.60 (1.78–5.43) 81.1% |
2.52 (1.02–4.02) 74.8% |
3.54 (0.91–6.17) 82.1% |
| Xenograft |
6.66 (3.38–9.94) 76% |
3.86 (1.20–6.52) 86.8% |
2.85 (1.62–4.07) 19.5% |
| Secretome | |||
| Source of MSCs | |||
| Adipose |
3.67 (2.26–5.08) 0% |
4.83 (− 2.26–12.16) 81.1% |
– |
| Umbilical Cord |
2.78 (0.97–4.58) 78.1% |
4.10 (3.20–4.99) 8.4% |
3.25 (1.89–4.61) |
| iPS-derived MSCs | 2.71 (− 0.23–5.64) | 5.55 (0.26–10.84) | – |
Selection
Two researchers (A.H.A and D.M) independently screened the titles and abstracts of the retrieved articles using the web-based software Rayyan to identify potentially relevant studies [34]. Following this initial screening, the full texts of the studies were independently reviewed by the same two researchers to determine their eligibility based on the predefined inclusion and exclusion criteria. In cases of disagreement between the two researchers, the final decision was made in consultation with the corresponding author (A.A).
Data collection
For data extraction from primary studies, two independent reviewers (A.H.A and A.A) utilized a standardized checklist in Excel. The extracted general data included the author's name, publication year, animal model, animal strain, gender and age of the animals, burn model, burn wound creation method, type of MSCs, type of secretome, isolation methods, characterization techniques, scaffold compositions, form, and characterization, as well as the structural and biological properties of the scaffolds. Additionally, for primary and secondary outcomes, the number of animals in control and treatment groups, the mean values of each outcome, the standard deviation (SD), and bar graphs were extracted. In cases where mean values or standard deviations were not explicitly reported, the WebPlotDigitizer 4.6 software was used to extract numerical data from graphs [35].
Risk of bias assessment
The methodological quality and potential sources of bias in the included studies were meticulously assessed using the SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) Risk of Bias Tool for animal studies [36]. Two independent researchers (A.H.A and D.M) evaluated each study across the nine key domains outlined in the SYRCLE tool: sequence generation, baseline characteristics, allocation concealment, random housing, blinding of caregivers and investigators, random outcome assessment, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting. Based on this comprehensive evaluation, each study was categorized as having a low, high, or unclear risk of bias. In cases where discrepancies arose between the two researchers regarding the risk of bias ratings, these were resolved through discussion and consultation with the corresponding author to reach a consensus.
Data analysis
In this meta-analysis, the standardized mean differences (SMD) along with their 95% confidence intervals (CI) were utilized as effect size measures to evaluate the therapeutic effects of the synergistic combination of MSCs and scaffolds on both primary and secondary outcomes. To interpret the magnitude of the SMD values, the following thresholds were applied: SMD values between −0.2 and −0.5 were considered small, values ranging from −0.5 to −0.8 were classified as moderate, and values exceeding −0.8 were deemed large [37]. Given the methodological heterogeneity observed across the primary studies, the Random Effects Model (REM) was employed to pool the SMD effect sizes [38]. To assess the degree of heterogeneity among the included studies, the Chi-square test and I2 statistic were applied. Additionally, publication bias was evaluated using Egger’s and Begg’s tests, funnel plot analysis, and the trim-and-fill method [39, 40]. Following these assessments, a sensitivity analysis was conducted to examine the robustness of the findings [41]. All statistical analyses were performed using R version 3.6.0, and p-values less than 0.05 were considered statistically significant.
Results
Study selection process
The PRISMA flow diagram illustrating the literature search process is presented in Fig. 1. Based on a systematic search across the specified databases, a total of 3,245 articles were initially retrieved. These included 539 articles from Embase, 1037 from PubMed, 847 from Scopus, 770 from Web of Science, and 16 from ProQuest. After removing 1388 duplicate records, two researchers independently screened the titles and abstracts of 1857 articles. Of these, 1,806 articles were excluded due to non-compliance with the inclusion and exclusion criteria. The full texts of 51 articles were assessed, and ultimately, 27 primary studies were selected for data extraction [27, 29, 42–66]. The remaining 24 articles were excluded for the following reasons: they did not focus on burn injuries, lacked direct or indirect data extraction possibilities, used alternative effect size metrics, did not utilize MSCs, or employed bilayered scaffolds.
Fig. 1.
PRISMA flow diagram detailing study screening and selection
Study characteristics
Animal models
Among the included studies, 14 studies utilized mice, 11 studies employed rats, one study used rabbits, and one study involved pigs (Fig. 2A). Of these, 16 studies focused on male animals, six studies on female animals, and one study included both sexes (Fig. 2B). The sex of the animals was not reported in four studies. Regarding the burn models, 16 studies induced third-degree burns, nine studies created second-degree burns, and the burn model was not specified in two studies (Fig. 2C). The methods employed to induce burns, along with other relevant information pertaining to the animal model, are concisely presented in Table 1.
Fig. 2.
Comperhensive overview of included study characteristics
Mesenchymal stem cells
Out of the 20 studies that utilized MSCs, 11 studies employed animal-derived MSCs, while nine studies used human-derived MSCs (Fig. 2D). Specifically, 11 studies used adipose tissue-derived MSCs, six studies utilized bone marrow-derived MSCs, and three studies employed umbilical cord-derived MSCs (Fig. 2E). A summary of the points mentioned, along with the methods for identifying and characterizing MSCs based on ISCT guidelines [67], is provided in Table 2.
Secretome
According to Table 3, among the seven studies that isolated MSCs, three studies focused on exosomes, one study investigated microvesicles, one study examined small extracellular vesicles, one study analyzed paracrine proteins, and one study utilized conditioned medium (Fig. 2F). Of these, four studies investigated secretomes derived from umbilical cord MSCs, two studies explored secretomes from adipose-derived MSCs, and one study used secretomes from iPSC-derived MSCs (Fig. 2G). For isolation, four studies employed ultrafiltration, and three studies used ultracentrifugation as the primary methods.
Scaffold types
In terms of scaffolds, six studies utilized biological-based scaffolds, while 21 studies employed hydrogel-based scaffolds (Fig. 2H). The hydrogel formulations included injectable hydrogels, foam hydrogels, amorphous hydrogels, film hydrogels, freeze-dried hydrogels, nanofiber hydrogels, and bioprinted hydrogels (Fig. 2I). The most commonly used biomaterials in these hydrogels were hyaluronic acid, collagen, chitosan, gelatin, and alginate (Fig. 2J). The information provided pertains to scaffolds, including Scaffold Compositions, Forms, and characterization methods, as well as the Structural and Biological Properties of scaffolds, all of which are comprehensively presented in Table 4.
Result of risk of bias assessment
The risk of bias assessment, conducted using the SYRCLE tool, yielded the following findings across the included studies. In the domain of selection bias, under the subcategory of sequence generation, 18 out of 27 studies (66.7%) were classified as having a low risk of bias. In the baseline characteristics subcategory, all but one study—i.e., 26 out of 27 studies (96.3%)—were deemed to have a low risk of bias. However, in the allocation concealment subcategory, all studies were rated as having an unclear risk of bias. In the domain of performance bias, the random housing subcategory indicated that 15 out of 27 studies (55.6%) were at low risk of bias, whereas in the blinding subcategory, all studies were assessed as having an unclear risk of bias. Regarding detection bias, the random outcome assessment subcategory showed that, with the exception of three studies, the remaining 24 out of 27 studies (88.9%) were classified as low risk. In contrast, the blinding subcategory within this domain revealed that all studies had an unclear risk of bias.In the domain of attrition bias, all but three studies—i.e., 24 out of 27 studies (88.9%)—were determined to have a low risk of bias. Finally, in the domain of reporting bias, all studies were consistently rated as having a low risk of bias. In total, of the 27 studies evaluated, 19 studies (70.4%) were classified as having an overall low risk of bias and were included in our review, while the remaining 8 studies (29.6%) were deemed to have an unclear risk of bias (Fig. 3). Also, to examine the impact of studies with unclear risk of bias on potential under- or overestimation of results, a subgroup analysis was conducted for the primary outcome. As shown in Table 5 and (Supplementary Data S2), these studies did not significantly influence the overall findings.
Fig. 3.
Quality assessment of individual studies using SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) tool
Primary outcome
Our analysis demonstrates that the synergistic effect of MSCs and scaffolds significantly improves wound closure rates, measured as the primary outcome, across three time frames. To evaluate the progression of wound healing, these time points were categorized as short-term (1-week), mid-term (2 weeks), and long-term (3 weeks). These intervals align with the inflammatory, proliferative, and remodeling phases of the wound healing process, respectively, and were selected based on standard practices in preclinical burn wound research. Moreover, these time points were chosen due to their frequent reporting in the scientific literature, enabling standardization and comparison of results across studies. These results are derived from 23 studies for the 1-week time point, 25 studies for 2 weeks, and 12 studies for 3 weeks. The effect was most pronounced at 1 week (SMD = 3.97, 95% CI: 2.92 to 5.01), followed by 2 weeks (SMD = 3.47, 95% CI: 2.23 to 4.61), and 3 weeks (SMD = 3.03, 95% CI: 1.96 to 4.11) (Fig. 4A–C). These results indicate that the combination of MSCs and scaffolds is highly effective in promoting wound healing, with the strongest impact observed in the early stages. However, the high heterogeneity (I2 > 50%) across studies suggests variability in experimental conditions, which should be considered when interpreting these findings.
Fig. 4.
Forest plot demonstrating the therapeutic efficacy of MSC-scaffold combinations in promoting wound closure in a burn animal model. A Week 1, B Week 2, C Week 3
Subgroup analysis and meta-regression
Due to the presence of high heterogeneity and to investigate its underlying causes as well as identify factors influencing therapeutic efficacy, we conducted a subgroup analysis across three time frames: 1 week, 2 weeks, and 3 weeks. The results revealed noteworthy findings (all results are available in Table 5 and Supplementary Data S2). Our results indicate that, in the comparison between the use of MSCs and MSC-derived secretome, the administration of MSCs (SMD = 4.75, 95% CI: 3.15 to 6.36) demonstrated superior therapeutic efficacy in the short term (1-week) compared to secretome (SMD = 2.90, 95% CI: 1.77 to 4.03). However, in the medium term (2-week) and long term (3-week), specifically in 2-week the therapeutic efficacy of secretome (SMD = 3.94, 95% CI: 2.30 to 5.58) was greater than that of MSCs (SMD = 3.20, 95% CI: 1.71 to 4.68). I2 analysis in this subgroup suggests that one of the main sources of heterogeneity was the inclusion of MSCs and MSC-derived secretome combined with scaffolds. Separate analysis of these combinations reduced heterogeneity; however, due to the limited number of secretome studies, we included both scaffold-based MSC and secretome data in the pooled results. The investigation of the therapeutic efficacy of MSCs across various animal models indicates a significant reduction in I2 (heterogeneity). This suggests that the choice of animal model utilized in the studies may be one of the key factors contributing to the heterogeneity observed in our results. The evaluation of the therapeutic efficacy of MSCs in second- and third-degree burn models reveals significant findings. In the one-week time frame, the wound closure rate in second-degree burns (SMD = 3.95, 95% CI: 2.00 to 5.90) was notably sharp compared to third-degree burns (SMD = 6.36, 95% CI: 2.99 to 9.74). However, as might be expected, the therapeutic efficacy in the second and third weeks was better in second-degree burn models (SMD = 3.49, 95% CI: 1.41 to 5.56; SMD = 3.21, 95% CI: 0.99 to 5.43) compared to third-degree burns (SMD = 2.46, 95% CI: 0.31 to 4.60; SMD = 2.83, 95% CI: 1.64 to 4.01), respectively. Additionally, the reduction in I2 suggests that the type of burn model used may be one of the contributing factors to the heterogeneity observed in our results. In addition, the type of scaffolds used also significantly influences therapeutic efficacy. Our results demonstrate that, in the one-week time frame, MSCs combined with biological scaffolds exhibited superior therapeutic efficacy (SMD = 8.83, 95% CI: 0.76 to 16.90) compared to hydrogels (SMD = 4.02, 95% CI: 2.37 to 5.67). However, in the two- and three-week time frames, the therapeutic efficacy of hydrogels (SMD = 3.41, 95% CI: 1.89 to 4.93; SMD = 3.60, 95% CI: 1.31 to 5.89) was greater than that of biological scaffolds (SMD = 2.75, 95% CI: −0.54 to 6.04; SMD = 2.74, 95% CI: 1.56 to 3.91). The absence of a notable reduction in I2 within the scaffold type subgroup can be attributed to the substantial variation in scaffold nature (i.e., polymer-based vs. biological-based scaffolds) and in their constituent components (i.e., natural or synthetic biomaterials). This broad variability in both structural origin and material composition likely contributes to the persistent heterogeneity observed, which may, in turn, affect the robustness and certainty of the derived conclusions.The type of MSCs used significantly influences both heterogeneity and therapeutic efficacy. Our analysis highlights distinct performance patterns across different MSC sources—Umbilical Cord, Bone Marrow, and Adipose—over one-, two-, and three-week time frames. Umbilical Cord-derived MSCs demonstrated the highest therapeutic efficacy in the short term, with a SMD of 6.74 (95% CI: 4.88 to 8.60) at one week. This efficacy remained robust at two weeks (SMD = 6.30, 95% CI: 4.03 to 8.56) but declined slightly by three weeks (SMD = 3.29, 95% CI: 0.64 to 5.94). Similarly, Bone Marrow-derived MSCs exhibited strong therapeutic effects, with an SMD of 6.27 (95% CI: 4.74 to 7.81) at one week, 4.27 (95% CI: 1.73 to 6.81) at two weeks, and 4.42 (95% CI: 1.83 to 7.02) at three weeks. In contrast, Adipose-derived MSCs showed comparatively lower efficacy across all time frames: SMD = 4.16 (95% CI: 1.27 to 7.05) at one week, 1.56 (95% CI: 0.01 to 3.10) at two weeks, and 1.51 (95% CI: −0.28 to 3.30) at three weeks. Furthermore, the observed reduction in I2 suggests that the source of MSCs is a key factor contributing to the heterogeneity in our results. Regarding the source of MSCs, the results demonstrate that human-derived MSCs exhibit significantly higher therapeutic efficacy compared to animal-derived MSCs in the one- and two-week time frames. Specifically, human-derived MSCs showed an SMD of 6.66 (95% CI: 3.38—9.94) at one week and 3.86 (95% CI: 1.20 to 6.52) at two weeks. In contrast, animal-derived MSCs displayed lower efficacy, with an SMD of 3.60 (95% CI: 1.78 to 5.43) at one week and 2.52 (95% CI: 1.02 to 4.02) at two weeks. However, the results in the three-week time frame present a contrasting pattern. Here, animal-derived MSCs demonstrated higher therapeutic efficacy (SMD = 3.54, 95% CI: 0.91 to 6.17) compared to human-derived MSCs (SMD = 2.85, 95% CI: 1.62 to 4.07). Regarding MSC-derived secretomes, our results indicate that secretomes extracted from Adipose-derived MSCs exhibit higher therapeutic efficacy compared to those from Umbilical Cord-derived MSCs in the one- and two-week time frames. Specifically, Adipose-derived secretomes demonstrated an SMD of 3.67 (95% CI: 2.26 to 5.08) at one week and 4.83 (95% CI: − 2.26 to 12.16) at two weeks. In contrast, Umbilical Cord-derived secretomes showed lower efficacy, with an SMD of 2.78 (95% CI: 0.97 to 4.58) at one week and 4.10 (95% CI: 3.20 to 4.99) at two weeks. These findings suggest that Adipose-derived MSC secretomes may offer superior therapeutic benefits in the short to medium term. Furthermore, the results of our meta-regression analysis indicate that no dose–response relationship was observed regarding the number of MSCs administered and their therapeutic efficacy across the three specified time frames (Supplementary Data S2). Also, given the absence of a universally established criterion for classifying sample sizes in preclinical studies, we categorized sample sizes based on the ARRIVE guidelines and the distribution of sample sizes in the included studies [68]. Specifically, we classified sample sizes as small (n < 6, below the minimum recommended threshold), sufficient (n = 6–11), or large (n > 11). Our analysis revealed that, of the 27 included studies, 12 were classified as small, 13 as sufficient, and 2 as large. This distribution suggests that the overall sample sizes are sufficient to ensure the reliability of the meta-analytic results. Furthermore, subgroup analysis based on sample size across all three time frames demonstrated that the greatest therapeutic efficacy was observed in the adequate sample size group. Consequently, smaller sample sizes did not significantly influence the intervention outcomes and were not a determining factor in the strength of the evidence.
Secondary outcomes
Angiogenesis
Our analytical results demonstrate that the synergistic effect of MSCs and scaffolds significantly enhances the expression of CD31, a key marker of angiogenesis (SMD = 6.24, 95% CI: 3.90 to 8.58) (Fig. 5A). This finding underscores the potential of combining MSCs and scaffolds to promote vascularization, which is critical for effective tissue repair and regeneration. However, the I2 values exceeding 50% for both parameters indicate high heterogeneity among the studies included in the analysis.
Fig. 5.
Forest plot demonstrating the therapeutic efficacy of MSC-scaffold combinations on: A angiogenesis, B collagen deposition, C inflammatory cytokines, D growth factors
Collagen
The findings from our analysis highlight that the synergistic interaction between and scaffolds significantly enhances collagen deposition at burn wound sites (SMD = 4.97, 95% CI: 2.22 to 7.73) (Fig. 5B). This suggests that the combined application of MSCs and scaffolds plays a pivotal role in promoting tissue regeneration and improving wound healing outcomes. However, the high heterogeneity observed, as indicated by I2 values exceeding 50%, points to substantial variability across the studies included in this analysis.
Inflammatory cytokines
Our analysis reveals that the combined use of MSCs and scaffolds exerts a powerful anti-inflammatory effect, significantly lowering the levels of pro-inflammatory cytokines. Specifically, we observed notable reductions in TNF-α (SMD = − 4.06, 95% CI: − 1.72 to −6.4), IL-6 (SMD = − 6.24, 95% CI: − 2.23 to −10.26), and IL-1 (SMD = − 5.13, 95% CI: − 1.69 to −8.56) (Fig. 5C). These results suggest that the interaction between MSCs and scaffolds plays a critical role in dampening inflammatory pathways, which could have significant implications for therapeutic strategies in inflammatory diseases and tissue repair. However, the high heterogeneity reflected by I2 values exceeding 50% for all three cytokines indicates considerable variability across the studies analyzed.
Growth factors
The results of our analyses indicate that the synergistic effect of MSCs and scaffolds significantly enhances the expression of key growth factors, including TGF-β (SMD = 6.21, 95% CI: − 1.6 to 14.03) and VEGF (SMD = 7.30, 95% CI: 4.85 to 9.75) (Fig. 5D). The observed effect sizes suggest a substantial impact of this combination on promoting growth factor activity. However, the I2 values exceeding 50% for both parameters indicate high heterogeneity among the studies included in the analysis.
Publication bias
To assess publication bias, we employed three widely used methods: the trim and fill method, funnel plot analysis, and Egger’s and Begg’s tests. According to Table 6, for the primary outcome, the asymmetric distribution in the funnel plot and the addition of studies in the trim and fill method across all three time frames suggest the presence of significant publication bias. Furthermore, Egger’s and Begg’s tests yielded p-values < 0.05 at the 1-week and 2-week time points, further supporting the existence of notable publication bias. However, at the 3-week time point, the p-values from Egger’s and Begg’s tests exceeded 0.05, indicating no significant evidence of publication bias during this period. The evaluation of publication bias for secondary outcomes also revealed notable findings. For CD31 expression, inflammatory cytokines, and growth factors, the asymmetric distribution in the funnel plot, the addition of studies in the trim and fill method, and Egger’s test with p-values < 0.05 all indicate significant publication bias. However, Begg’s test yielded p-values of 0.11, 0.12, and 0.76, respectively. The asymmetric funnel plot, the addition of studies in the trim and fill method, and Begg’s test with a p-value < 0.05 suggest significant publication bias. In contrast, Egger’s test showed a p-value of 0.11 (all results are available in Supplementary Data S3).
Table 6.
Summary of publication bias and sensitivity analysis resualts for outcomes
| Outcomes | Publication bias | Sensitivity analysis | |||
|---|---|---|---|---|---|
| Funnel plot | Begg’s P value | Egger’s P value | Trim and fill | ||
|
Wound closure (1 week) |
Asymmetric pattern | 0.005 | < 0.001 | 11 study added | Without outlier studies |
|
Wound closure (2 week) |
Asymmetric pattern | 0.008 | 0.008 | 9 study added | Without outlier studies |
|
Wound closure (3 week) |
Asymmetric pattern | 0.243 | 0.082 | 3 study added | Without outlier studies |
| Angiogenesis | Asymmetric pattern | 0.117 | 0.006 | 5 study added | Without outlier studies |
| Collagen | Asymmetric pattern | 0.022 | 0.707 | 3 study added | Without outlier studies |
| Inflammatory cytokines | Asymmetric pattern | 0.119 | 0.002 | 6 study added | Without outlier studies |
| Growth factors | Asymmetric pattern | 0.763 | 0.004 | 4 study added | Without outlier studies |
Sensitivity analysis
For sensitivity analysis, we employed the one-out remove method to assess the influence of individual studies on the SMD as the effect size metric. According to Table 6, for both the primary outcome and secondary outcomes, the one-out remove method revealed that no outlier studies were identified, indicating that no single study had a significant impact on the overall SMD. This suggests that the results are not disproportionately influenced by any individual study (all results are available in Supplementary Data S4).
Discussion
Burn injuries pose significant medical and psychological challenges for affected individuals and remain a major public health concern [9]. Despite advancements in clinical management, current treatment strategies are still suboptimal and face notable limitations [69]. In recent years, increasing attention has been directed toward the use of MSCs and their secretome due to their anti-inflammatory, regenerative, and reparative properties, which are crucial for damaged tissue. However, the clinical application of MSCs alone is hindered by poor survival and differentiation of transplanted cells [70]. Tissue engineering, by combining MSCs with scaffolds like hydrogels, shows great promise for improving burn healing. Preclinical evidence highlights their synergistic effect in accelerating wound repair. This review systematically analyzes diverse methods to guide safer, cost-effective therapies, revealing enhanced wound closure in burn models.This effect is most pronounced in the short term (one week), followed by a moderate effect in the mid-term (two weeks) and a sustained, but comparatively lower, effect in the long term (three weeks). Based on interpretative thresholds, this therapeutic effect is considered large. The temporal pattern of efficacy observed in our meta-analysis may be mechanistically explained by the dynamic nature of wound healing. During the early inflammatory and proliferative phases, MSCs actively secrete a broad array of trophic factors—including VEGF, TGF-β, IGF-1, and IL-10—that promote neovascularization, attenuate inflammation, and stimulate fibroblast activation and matrix deposition. When delivered within a biocompatible scaffold, MSCs exhibit improved viability, engraftment, and localized bioactivity, amplifying these effects. The scaffold also provides mechanical support and mimics the native extracellular matrix, thereby facilitating cell–matrix interactions critical for early-stage tissue regeneration. As healing progresses into the remodeling phase, endogenous regenerative mechanisms begin to dominate, and the additive benefit of exogenous cell-based therapies may diminish, reflecting the reduced inflammatory milieu and cellular responsiveness at later stages. Thus, the observed early-phase synergy likely stems from both the heightened biological activity of MSCs and the scaffold’s supportive microenvironment during the critical initial phases of tissue repair. Consistent with our findings, Yi et al.[30] reported that MSCs alone substantially improve wound closure rates. However, compared to their results, our analysis indicates that the combined use of MSCs with scaffolds leads to superior outcomes in animal models, highlighting the additional benefits of scaffold-based delivery. Nevertheless, further preclinical studies are necessary to refine our understanding of the therapeutic efficacy of MSCs alone versus their combined application with scaffolds. Similarly, in alignment with our results, Yuan Li et al. [71]. demonstrated the therapeutic potential of various stem cells in promoting burn wound healing in animal models. Specifically, Kohlhauser et al. [72]. highlighted the regenerative effects of adipose-derived stem cells, reinforcing the broader applicability of stem cell therapy in burn management. Beyond burns, the therapeutic potential of MSCs has also been observed in other skin injuries. For instance, Yuan Li et al. [73]. reported that stem cell therapy significantly reduces skin flap necrosis, further supporting the regenerative capabilities of MSCs in diverse dermatological applications. Subgroup analysis based on various factors was conducted, and the comparison between MSCs and MSC-derived secretome revealed that secretome-based therapy significantly enhances burn wound closure in animal models, demonstrating effects comparable to MSC therapy. This finding underscores the importance of secretome as a cell-free therapy, emphasizing its regenerative and anti-inflammatory properties [24]. Consistent with our results, Yujia Yang et al. [74]. also demonstrated that exosome-based therapies derived from various cell sources, when combined with hydrogel scaffolds, could effectively promote wound healing in different wound types, including burns, diabetic foot ulcers, and excisional wounds. Their findings support the potential of optimized cell-free therapeutic approaches for wound management. Furthermore, the therapeutic potential of MSC-derived secretome as a cell-free therapy extends beyond wound healing. Previous studies have highlighted its beneficial effects in conditions such as liver and kidney failure and sepsis, further reinforcing its regenerative potential [75–77]. However, additional preclinical studies are required to validate our findings and facilitate the clinical translation of secretome-based therapies. Regarding the source of MSC-derived secretome, our results indicate that secretome from adipose-derived MSCs exhibits superior effects compared to secretome from umbilical cord-derived MSCs. Additionally, a single study reporting the effects of iPS-derived MSCs has drawn attention to the potential of this cell source [27]. Given its significance and the limited research available, we propose that future preclinical studies should focus more on iPS-derived MSCs as an underexplored yet promising source. However, due to the limited number of studies, definitive conclusions cannot yet be drawn. Further preclinical investigations are essential to comprehensively compare different MSC sources, enabling more reliable conclusions regarding their therapeutic potential. Furthermore, in the subgroup analysis specifically evaluating MSCs in combination with scaffolds based on the model of burn injury, our findings indicate that wound closure in third-degree burns significantly improves in the short term. Additionally, in second-degree burns, wound closure shows greater improvement over medium- and long-term timeframes compared to third-degree burns. These results suggest that this therapeutic approach may be particularly effective in the early stages of third-degree burns, a critical and sensitive phase in burn management where rapid intervention is essential. Also, our findings indicate that UC-MSCs exhibit the highest therapeutic efficacy among the evaluated MSC sources. This superiority can be attributed to several advantages, including high proliferative capacity, non-invasive cell harvesting, reduced ethical concerns, lower risk of infection, minimal teratoma formation, and low immunogenicity with immunosuppressive properties [78–80]. However, UC-MSCs also present certain limitations, such as restricted availability, low survival rates in vivo, and lower differentiation potential compared to other MSC sources [80, 81]. Following UC-MSCs, BM-MSCs demonstrated the second-highest therapeutic effectiveness. Notably, BM-MSCs outperformed other sources specifically within the three-week timeframe, which may be attributed to their rapid proliferation, prolonged differentiation capacity, and extended functional lifespan [80, 82]. However, the use of BM-MSCs comes with significant challenges, including invasive and painful cell harvesting, limited self-renewal ability, a substantial decline in cell number, differentiation potential, and lifespan with aging, as well as increased susceptibility to contamination [83, 84]. Among the evaluated sources, AD-MSCs exhibited the lowest therapeutic efficacy. This may be attributed to inherent limitations such as restricted self-renewal capacity, prolonged proliferation period, and lower differentiation potential [80]. Nevertheless, AD-MSCs offer notable advantages, including easy accessibility, abundant availability, less invasive extraction, high metabolic activity, and enhanced cellular function [80, 85]. Despite these findings, definitive conclusions cannot yet be drawn. Therefore, we recommend further preclinical studies to comprehensively evaluate different MSC sources and determine the most optimal source for clinical applications. Interestingly, our analysis revealed a paradoxical trend wherein AD-MSCs exhibited the lowest efficacy among all MSC sources in enhancing burn wound healing, while their secretome outperformed secretomes derived from other MSC types in terms of regenerative potential. This discrepancy may be attributed to inherent biological differences between the cells and their secreted factors. The AD-MSC secretome is particularly rich in key pro-regenerative mediators, including bFGF and platelet-derived growth factor (PDGF), which are known to enhance fibroblast proliferation, collagen deposition, and re-epithelialization—processes central to effective burn repair [86]. Moreover, the AD-MSC secretome possesses strong antioxidant activity that may alleviate oxidative stress within the burn microenvironment, thereby preserving dermal cell integrity [87]. In contrast, the reduced efficacy of whole AD-MSCs may reflect their comparatively limited self-renewal and differentiation potential. These findings underscore the need for further mechanistic studies, particularly proteomic and transcriptomic profiling, to unravel the precise bioactive constituents responsible for these divergent effects and to inform the rational optimization of secretome-based therapies. Also, our subgroup analysis on MSC sources indicates that human-derived MSCs significantly enhance wound closure in the short and medium term, which may be attributed to the superior extraction and higher quality of these cells. However, in the long term, animal-derived MSCs demonstrate greater efficacy in promoting wound closure. A potential explanation for this observation could be related to the allogeneic versus xenogeneic nature of transplantation [88, 89]. Specifically, xenogeneic MSCs—originating from a different species—may provide a more potent paracrine stimulus during the early phases of wound healing, characterized by acute inflammation and rapid tissue regeneration. This heightened secretory activity likely accelerates initial wound closure despite the immunological challenges inherent to xenotransplantation. However, these cells are also more susceptible to immune clearance over time, which limits their sustained presence and reparative capacity. In contrast, allogeneic MSCs, derived from the same species as the host, generally induce a more favorable immunomodulatory response and exhibit enhanced immune tolerance, facilitating longer survival, engraftment, and sustained therapeutic effects. This immune compatibility likely underpins the superior long-term wound healing outcomes observed with allogeneic MSC applications. Thus, these findings suggest a biphasic effect where xenogeneic MSCs provide a strong initial regenerative stimulus, while allogeneic MSCs ensure prolonged therapeutic support. Ultimatliy, our subgroup analysis on scaffold types indicates that in the short term, the combination of MSCs with biological scaffolds exhibits high therapeutic efficacy, significantly enhancing wound closure. However, in the medium and long term, hydrogels demonstrate superior therapeutic effects. The differential therapeutic efficacy of biological scaffolds and hydrogels in burn wound healing stems from their distinct biological and structural properties, which align with the dynamic requirements of the wound healing phases [90]. Biological scaffolds, such as human Amnion membrane (AM), are highly effective in the early inflammatory phase due to their native extracellular matrix (ECM) rich in collagen, laminin, and growth factors like TGF-β and VEGF [91]. These components create a biomimetic microenvironment that enhances MSC adhesion, survival, and paracrine signaling, while their anti-inflammatory properties reduce pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and promote M2 macrophage polarization, facilitating rapid inflammation resolution and early wound closure [92, 93]. Hence, the superior short-term effects of biological scaffolds observed in our study’s results can likely be attributed to these mechanisms. Conversely, hydrogels, composed of polymers like hyaluronic acid or collagen, excel in the proliferative and remodeling phases due to their tunable mechanical properties and controlled release of bioactive molecules [94]. These scaffolds maintain a moist wound environment, support sustained MSC proliferation and differentiation, and promote angiogenesis and collagen deposition over extended periods [95]. Therefore, the enhanced medium- and long-term effects of hydrogel scaffolds observed in our study’s results can likely be attributed to these mechanisms. On the other hand, another potential reason for this difference can be attributed to the rapid degradation of biological scaffolds (e.g., AM within 1–2 weeks), in contrast to the tunable degradation profiles of hydrogels, which can persist for weeks to support ongoing tissue repair [96, 97]. Given the limited number of studies available for direct comparison and the lack of comprehensive knowledge in this area, we strongly recommend further research focusing on comparative studies between different scaffold types using the same MSC source. This approach would provide a clearer understanding of their respective roles in optimizing MSC-based combination therapies for wound healing. Furthermore, our regression analysis based on different MSC concentrations did not reveal a dose–response relationship [98, 99]. The absence of such a relationship may be attributed to several factors. First, the considerable heterogeneity among studies may have influenced the results. Second, the possibility of a nonlinear dose–response effect could also explain these observations. In evaluating subgroup analyses for primary outcomes, reduced heterogeneity in some groups suggests an influential factor, yet variability persists across groups, affecting evidence certainty.Therefore, for future meta-analyses, it is recommended to focus on investigating the therapeutic effects of burn treatment using cells or secretome, given the growing interest in cell-free therapies, and their integration with similar or unique scaffolds, such as injectable hydrogels, 3D-printed scaffolds, and biological-based scaffolds. This approach aims to reduce heterogeneity, thereby yielding more consistent and reliable results.While our meta-analysis broadly evaluates the synergistic effects of MSCs and scaffolds in burn wound healing, special consideration was given to radiation-induced cutaneous wounds (RCSWs), which present with complex tissue damage and delayed healing—pathophysiologically similar to deep burns such as 4th-degree injuries and scalds. Three included studies provided valuable insights in this regard. Fang et al. reported that MSC-derived sEVs, combined with polydopamine nanoparticle-containing hydrogels, effectively reduced oxidative stress and enhanced angiogenesis in RCSWs [46]. Peng et al. demonstrated that quaternized chitosan/sodium alginate hydrogels loaded with exosomes exhibited antimicrobial protection and accelerated re-epithelialization in radiation-combined injuries, relevant to infected deep burns [27]. Yao et al. employed metformin-preconditioned microneedle patches loaded with mitochondria-enriched microvesicles to restore mitochondrial function and induce anti-inflammatory macrophage polarization, showing potential for treating severe, scar-prone wounds [63]. These findings underscore the promise of MSC-based scaffold therapies in managing complex burn injuries, though further studies are warranted to refine these approaches for deep and scald burns. Regarding our secondary outcomes, the combination of MSCs and scaffolds was found to enhance angiogenesis. Consistent with our findings, a study by Yujia Yang et al. [74]. demonstrated that exosome-based therapies with hydrogel scaffolds also promote angiogenesis in diabetic wounds and other types of wounds. Angiogenesis plays a crucial role in wound and burn healing, as it facilitates oxygen and nutrient delivery, accelerates tissue regeneration, and supports immune cell infiltration, all of which are essential for effective wound closure [100]. Impaired angiogenesis is a major contributing factor to chronic wounds and delayed healing, particularly in conditions such as diabetes and severe burns [101]. Therefore, therapies that enhance angiogenesis, such as MSC-based treatments and scaffold-assisted delivery systems, hold great promise for improving vascularization and overall wound healing outcomes. In this meta-analysis, angiogenesis was predominantly assessed using CD31 (PECAM-1), a well-established endothelial marker. CD31 allows for standardized and quantitative evaluation of neovascular structures, typically reported as vessel count per field or area. Although angiogenesis is inherently complex and involves multiple pathways and cell types, CD31 was chosen based on its frequent and consistent use across included studies, which enabled statistically valid comparisons. However, given the availability of additional markers such as CD34, as well as functional assessments like perfusion imaging, future preclinical studies could incorporate these parameters to enhance the accuracy and quality of angiogenesis analyses, thereby providing a more comprehensive and physiologically relevant evaluation of neovascularization.The combination of MSCs and scaffolds significantly enhances collagen deposition at the burn wound site. Our findings are consistent with the study by Tian Yuan, which demonstrated that exosomes derived from human adipose-derived stem cells can lead to increased collagen types I and III at the wound healing site [102]. Increased collagen production is crucial for extracellular matrix formation, strengthening the wound, and promoting effective tissue remodeling [103, 104]. Similar to angiogenesis, collagen deposition was reported using quantifiable markers—mainly collagen I and III—through histological staining or immunohistochemistry, facilitating meta-analytic synthesis.This highlights the potential of MSC-based therapies combined with scaffolds for supporting both vascularization and structural regeneration in burn healing. The combination of MSCs and scaffolds demonstrates a strong anti-inflammatory effect, significantly reducing levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α. This immune modulation is critical for promoting wound healing, as it prevents chronic inflammation, which can hinder tissue regeneration [105].In line with our findings, Yujia Yang et al. [74]. showed that exosome-based therapies with hydrogel scaffolds also reduce IL-6 and TNF-α levels in various types of wounds. The combination of MSCs and scaffolds significantly increases the levels of growth factors such as TGF-β and VEGF. These growth factors play a crucial role in tissue repair, angiogenesis, and extracellular matrix remodeling, all of which are essential for effective wound healing [106]. Although these markers reflect only segments of the broader biological processes, they were the most consistently and numerically reported outcomes in the included studies, enabling meaningful comparisons. Given the limited number of studies on all secondary outcomes, we recommend that future studies focus on further examining these effects in animal models to provide more robust and conclusive evidence supporting our findings. However, it is essential to acknowledge that the I2 values for all secondary outcomes exceeded 50%, indicating considerable heterogeneity among the included studies. This substantial variability may be attributed to several critical factors, including differences in scaffold composition and structural properties, inconsistent methodologies used for outcome assessment, and variability in the cellular sources of MSCs. Furthermore, the meta-analysis incorporated both studies utilizing intact MSCs and those employing MSC-derived secretomes, potentially amplifying biological heterogeneity. These methodological and biological inconsistencies not only complicate the interpretation of pooled outcomes but also highlight the urgent need for standardized experimental protocols, harmonized reporting criteria, and stratified analyses in future preclinical investigations to ensure more accurate and generalizable conclusions.
Clinical translation
Our meta-analysis establishes the robust preclinical efficacy of MSC and scaffold combinations in burn wound healing. These findings lay a solid foundation for clinical translation; however, challenges such as study heterogeneity and limited clinical data must be addressed to fully realize their therapeutic potential. Emerging clinical evidence supports the safety and efficacy of MSC-based therapies in burn wound treatment. A phase I clinical trial (NCT02104713) evaluating BM-MSCs in deep second-degree burns reported complete wound closure in all 10 participants [107]. Improvements in the Patient and Observer Scar Assessment Scale (POSAS) scores, alongside enhanced pigmentation and hair follicle regeneration, underscore the regenerative potential of MSCs [107]. Another trial (NCT02394873) confirmed the safety of AD-MSCs combined with hydrogel sheets in deep second-degree burns, reporting no significant adverse events [108]. Additionally, a phase I trial (NCT05078385) exploring MSC-derived EVs suggests that acellular therapies may offer safer, scalable alternatives. These clinical findings align with our preclinical results, particularly the synergy of MSCs with scaffolds and the promise of secretome-based approaches, indicating a viable path for clinical application. Our subgroup analyses also offer strategies to mitigate study heterogeneity and translational barriers. For example, the efficacy of MSC-derived secretome—especially from AD-MSCs—indicates that acellular therapies could reduce variability related to cell source and delivery. The superior performance of UC-MSCs, likely due to their high proliferative capacity and low immunogenicity, makes them strong candidates for standardization, though their limited availability remains a challenge. Differential outcomes between second- and third-degree burns point to the importance of stratifying clinical trials by burn severity to improve consistency. Furthermore, the short-term effectiveness of biological scaffolds and the long-term benefits of hydrogels should inform scaffold selection. The current lack of a clear dose–response relationship also highlights the need for standardized dosing protocols to minimize heterogeneity. To address these translational challenges—including preclinical heterogeneity, limited clinical trial scale, and patient-specific variability—we propose the following strategies: (1) standardize the use of UC-MSCs or secretome therapies combined with hydrogels, (2) design randomized controlled trials stratified by burn severity, and (3) prioritize the development of acellular therapies to navigate regulatory barriers. By implementing these strategies, MSC-scaffold therapies can be optimized for clinical use, offering regenerative solutions for patients with burn injuries.
Limitation
There are as follows the restrictions of this systematic review and meta-analysis: First, Of the 27 studies included, only 6 provided directly extractable numerical data, necessitating the use of WebPlotDigitizer to extract data from graphs in the remaining 21 studies. While this software is a widely accepted tool for data extraction, its accuracy may be limited by factors such as poor image quality or visual constraints of the graphs, potentially introducing minor errors in identifying data points or scaling conversions, particularly for standard deviation (SD) and standard error of the mean (SEM) values. To mitigate these risks, data extraction was independently performed by two researchers, with results cross-verified to ensure maximum accuracy. Although these measures minimize potential inaccuracies, slight deviations may still impact the precision of the reported results. Second, the dependability of our comparisons in the analysis may suffer from notable methodological variance among the included research. Among the notable variances are those in animal models, burn degrees, kinds of mesenchymal stem cells employed, kinds of secretomes, different dosages given, and different scaffolds. Third, the scarcity of preclinical studies utilizing MSCs and scaffolds produced under Good Manufacturing Practice (GMP) requirements represents a significant limitation of our work [109, 110]. Clinical translation of MSC-scaffold combinations necessitates adherence to stringent GMP standards, as mandated by regulatory bodies such as the FDA and the EMA for Advanced Therapy Medicinal Products (ATMPs) [111–113]. These standards require rigorous testing for identity, purity, potency, and sterility, which poses substantial resource and infrastructural challenges [114]. The heterogeneity in the included trials, particularly the lack of GMP-compliant MSC and scaffold production, impedes their clinical applicability. To address this, we recommend that future research prioritize the evaluation of GMP-produced MSC-EVs and scaffolds. Such studies should focus on standardized protocols for cell processing, scaffold fabrication, and outcome assessment to enhance reproducibility and facilitate regulatory approval. Early collaboration with regulatory authorities and investment in GMP-compliant facilities will be critical to generating robust preclinical data, thereby improving clinical decision-making and advancing the translation of MSC-EV-based therapies for burn wound healing. Fourth, one key limitation of this meta-analysis is the reliance on single or limited biomarkers to represent complex biological processes such as angiogenesis, immune modulation, collagen remodeling, and growth factor activity. This approach was necessitated by the lack of standardized, consistently reported multi-marker data across the included studies. While markers such as CD31, VEGF, TNF-α, and collagen I/III provide measurable and widely used indicators, they offer only partial insight into the multifaceted biology of wound healing. Fifth, a limitation of our study is the lack of direct comparison between the combined MSC/MSC-secretome and scaffold approach and stand-alone interventions, such as MSCs alone, MSC-secretomes alone, or scaffolds alone. The absence of a meta-analysis including single-component treatments limits our ability to quantitatively assess the degree of synergy. However, heterogeneity in study design, outcome measures, and reporting precluded a robust meta-analysis of these comparisons. We acknowledge that such an analysis could further substantiate the synergistic benefits and enhance the relevance of our findings. Future studies should prioritize direct comparisons of combination versus single-component interventions in standardized preclinical models.
Conclusion
This systematic review and meta-analysis evaluated the synergistic effects of MSCs and scaffolds in preclinical burn wound healing studies. Our results demonstrate that combining MSCs and their secretome with scaffolds significantly enhances wound closure, collagen deposition, growth factor expression, and angiogenesis while modulating inflammatory cytokines. This approach holds promise as an adjunctive therapy to conventional burn treatments, with potential to improve regenerative outcomes. The study also identified optimal MSC sources and scaffold types, offering insights for therapeutic optimization. However, translating these findings into clinical practice is challenged by high study heterogeneity, including variations in animal models, scaffold designs, and outcome measures. Such inconsistencies limit the practical applicability of preclinical results. To address this, future research should standardize protocols and employ models that better reflect human burn pathophysiology. While MSC-scaffold synergy presents a compelling strategy for burn wound management, its clinical success depends on overcoming these limitations through rigorous validation. In summary, this combinatorial approach offers substantial therapeutic potential, but further refinement is essential for effective translation.
Supplementary Information
Supplementary Data S1-Search strategies.
Supplementary Data S2-Subgroup analysis.
Supplementary Data S4-Sensitivity Analysis.
Acknowledgements
We express our appreciation to AJA University of Medical Sciences for their support in conducting this project. We also extend our special gratitude to the Quillbot AI tool for its assistance in the editing and proofreading stages.
Author contributions
A.H.A: searching, selection process, quality control of studies, data collecting, statistical analysis and writing/D.A: selection process, quality control of studies and writing/A.A: quality control of studies, data collecting, and final editing/Z.J: searching, validation, and final editing.
Funding
Not applicable.
Data availability
The data examined in this research can be obtained from the corresponding author upon a reasonable request.
Declarations
Ethics approval consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors affirm that no conflicts of interest exist concerning this study.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Bonifant H, Holloway S. A review of the effects of ageing on skin integrity and wound healing. Br J Community Nurs. 2019;24(Sup3):S28-s33. [DOI] [PubMed] [Google Scholar]
- 2.Nielson CB, et al. Burns: pathophysiology of systemic complications and current management. J Burn Care Res. 2017;38(1):e469–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Jain M, Khadilkar N, De Sousa A. Burn-related factors affecting anxiety, depression and self-esteem in burn patients: an exploratory study. Ann Burns Fire Disasters. 2017;30(1):30–4. [PMC free article] [PubMed] [Google Scholar]
- 4.Spronk I, et al. Patient-reported scar quality of adults after burn injuries: a five-year multicenter follow-up study. Wound Repair Regen. 2019;27(4):406–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Peck MD. Epidemiology of burns throughout the world. Part I: distribution and risk factors. Burns. 2011;37(7):1087–100. [DOI] [PubMed]
- 6.Żwierełło W, et al. Burns: classification, pathophysiology, and treatment: a review. Int J Mol Sci. 2023;24(4). [DOI] [PMC free article] [PubMed]
- 7.Dean J, et al. Advancements in bioengineered and autologous skin grafting techniques for skin reconstruction: a comprehensive review. Front Bioeng Biotechnol. 2024;12:1461328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Alrubaiy L, Al-Rubaiy KK. Skin substitutes: a brief review of types and clinical applications. Oman Med J. 2009;24(1):4–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jeschke MG, et al. Burn injury. Nat Rev Dis Primers. 2020;6(1):11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dutra Alves NS, et al. Advances in regenerative medicine-based approaches for skin regeneration and rejuvenation. 2025;13. [DOI] [PMC free article] [PubMed]
- 11.Jorgensen AM, et al. Advances in skin tissue engineering and regenerative medicine. J Burn Care Res. 2023;44(Suppl_1):S33-s41. [DOI] [PMC free article] [PubMed]
- 12.Riha SM, Maarof M, Fauzi MB. Synergistic effect of biomaterial and stem cell for skin tissue engineering in cutaneous wound healing: a concise review. 2021;13(10):1546. [DOI] [PMC free article] [PubMed]
- 13.Kondej K, et al. Bioengineering skin substitutes for wound management-perspectives and challenges. Int J Mol Sci. 2024;25(7). [DOI] [PMC free article] [PubMed]
- 14.Mirshafiei M, et al. Advancements in tissue and organ 3D bioprinting: current techniques, applications, and future perspectives. Mater Des. 2024;240: 112853. [Google Scholar]
- 15.Sukmana BI, et al. Supporting wound healing by mesenchymal stem cells (MSCs) therapy in combination with scaffold, hydrogel, and matrix; State of the art. Pathol Res Pract. 2023;248: 154575. [DOI] [PubMed] [Google Scholar]
- 16.Zheng Y, et al. Hyperbranched polymers: advances from synthesis to applications; 2015. [DOI] [PubMed]
- 17.Ambrosio L. The role of biomaterials in burn treatment. Burns Trauma. 2014;2(4):150–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Song Y-T, et al. Extracellular matrix-based biomaterials in burn wound repair: a promising therapeutic strategy. Int J Biol Macromol. 2024;283: 137633. [DOI] [PubMed] [Google Scholar]
- 19.Ho TC, et al. Hydrogels: properties and applications in biomedicine. Molecules. 2022;27(9). [DOI] [PMC free article] [PubMed]
- 20.Revete A, et al. Advancements in the use of hydrogels for regenerative medicine: properties and biomedical applications. Int J Biomater. 2022;2022:3606765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Jamalpoor ZJT. Chitosan: a brief review on structure and tissue engineering application. JATE. 2014;1(1):3–6.
- 22.Rehman A, et al. Mesenchymal stem cells in soft tissue regenerative medicine: a comprehensive review. Medicina (Kaunas). 2023;59(8). [DOI] [PMC free article] [PubMed]
- 23.Li J, et al. Insights into the role of mesenchymal stem cells in cutaneous medical aesthetics: from basics to clinics. Stem Cell Res Ther. 2024;15(1):169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Vizoso FJ, et al. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18(9). [DOI] [PMC free article] [PubMed]
- 25.Han Y, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022;7(1):92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Manzoor T, et al. Exosomes in nanomedicine: a promising cell-free therapeutic intervention in burn wounds. Stem Cell Res Ther. 2024;15(1):355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Peng G, et al. Injectable exosome-loaded quaternized chitosan/oxidized sodium alginate hydrogel with self-healing, bioadhesive, and antibacterial properties for treating combined radiation-wound injury. Chem Eng J. 2024;494: 152933. [Google Scholar]
- 28.Foo JB, et al. Comparing the therapeutic potential of stem cells and their secretory products in regenerative medicine. Stem Cells Int. 2021;2021:2616807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Alapure BV, et al. Accelerate healing of severe burn wounds by mouse bone marrow mesenchymal stem cell-seeded biodegradable hydrogel scaffold synthesized from arginine-based poly(ester amide) and Chitosan. Stem Cells Dev. 2018;27(23):1605–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yi H, et al. Efficacy assessment of mesenchymal stem cell transplantation for burn wounds in animals: a systematic review. Stem Cell Res Ther. 2020;11(1):372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Jamalpoor Z, et al. In vitro interaction of human Wharton's jelly mesenchymal stem cells with biomimetic 3D scaffold. 2019;107(6):1166–75. [DOI] [PubMed]
- 32.Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387. [DOI] [PubMed] [Google Scholar]
- 34.Ouzzani M, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Rohatgi A. WebPlotDigitizer; 2018.
- 36.Hooijmans CR, et al. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Cohen J. Statistical power analysis for the behavioral sciences. Routledge; 2013.
- 38.Al Khalaf MM, Thalib L, Doi SA. Combining heterogenous studies using the random-effects model is a mistake and leads to inconclusive meta-analyses. J Clin Epidemiol. 2011;64(2):119–23. [DOI] [PubMed]
- 39.Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63. [DOI] [PubMed] [Google Scholar]
- 41.Sutton A, et al. Methods for meta-analysis in medical research. 2000:3–317.
- 42.A VT, et al. Fabrication and evaluation of gelatin/hyaluronic acid/chondroitin sulfate/asiatic acid based biopolymeric scaffold for the treatment of second-degree burn wounds—Wistar rat model study. Biomed Mater. 2020;5(5):055016. [DOI] [PubMed]
- 43.Banerjee J, et al. Delivery of silver sulfadiazine and adipose derived stem cells using fibrin hydrogel improves infected burn wound regeneration. PLoS ONE. 2019;14(6): e0217965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Barrera JA, et al. Adipose-derived stromal cells seeded in pullulan-collagen hydrogels improve healing in murine burns. Tissue Eng Part A. 2021;27(11–12):844–56. [DOI] [PubMed] [Google Scholar]
- 45.Cabello-Arista B, et al. Effects of mesenchymal stem cell culture on radio sterilized human amnion or radio sterilized pig skin in burn wound healing. Cell Tissue Bank. 2024;25(1):255–67. [DOI] [PubMed] [Google Scholar]
- 46.Fang Z, et al. A multifunctional hydrogel loaded with two nanoagents improves the pathological microenvironment associated with radiation combined with skin wounds. Acta Biomater. 2023;159:111–27. [DOI] [PubMed] [Google Scholar]
- 47.Ghaneialvar H, et al. Docosahexaenoic acid-loaded chitosan/alginate membrane reduces biofilm formation by P. aeruginosa and promotes MSC-mediated burn wound healing. J Biomater Appl. 2023;37(8):1458–69. [DOI] [PubMed]
- 48.Gholipour-Kanani A, et al. Tissue engineered poly(caprolactone)-chitosan-poly(vinyl alcohol) nanofibrous scaffolds for burn and cutting wound healing. IET Nanobiotechnol. 2014;8(2):123–31. [DOI] [PubMed] [Google Scholar]
- 49.Guo X, et al. Grafting of mesenchymal stem cell-seeded small intestinal submucosa to repair the deep partial-thickness burns. Connect Tissue Res. 2016;57(5):388–97. [DOI] [PubMed] [Google Scholar]
- 50.Liu P, et al. Tissue-engineered skin containing mesenchymal stem cells improves burn wounds. Artif Organs. 2008;32(12):925–31. [DOI] [PubMed] [Google Scholar]
- 51.Lu TY, et al. Enzyme-crosslinked gelatin hydrogel with adipose-derived stem cell spheroid facilitating wound repair in the murine burn model. Polymers (Basel). 2020;12(12). [DOI] [PMC free article] [PubMed]
- 52.Lu Y, et al. Amino acid-based protein-mimic hydrogel incorporating pro-regenerative lipid mediator and microvascular fragments promotes the healing of deep burn wounds. Int J Mol Sci. 2024;25(19). [DOI] [PMC free article] [PubMed]
- 53.Motamed S, et al. Cell-based skin substitutes accelerate regeneration of extensive burn wounds in rats. Am J Surg. 2017;214(4):762–9. [DOI] [PubMed] [Google Scholar]
- 54.Naasani LIS, et al. Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model. Biofabrication. 2022;15(1). [DOI] [PubMed]
- 55.Ng JY, et al. Pristine gellan gum-collagen interpenetrating network hydrogels as mechanically enhanced anti-inflammatory biologic wound dressings for burn wound therapy. ACS Appl Bio Mater. 2021;4(2):1470–82. [DOI] [PubMed] [Google Scholar]
- 56.Paramasivam T, et al. Effect of PDGF-B gene-activated acellular matrix and mesenchymal stem cell transplantation on full thickness skin burn wound in rat model. Tissue Eng Regen Med. 2021;18(2):235–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Rasouli M, et al. Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model. Arch Dermatol Res. 2024;316(7):353. [DOI] [PubMed] [Google Scholar]
- 58.Shahmohammadi A, et al. Burn wound healing using adipose-derived mesenchymal stem cells and manganese nanoparticles in polycaprolactone/gelatin electrospun nanofibers in rats. Bioimpacts. 2024;14(5):30193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Wang S, et al. Versatile hydrogel dressings that dynamically regulate the healing of infected deep burn wounds. Adv Healthc Mater. 2023;12(30): e2301224. [DOI] [PubMed] [Google Scholar]
- 60.Wang Y, et al. Mesenchymal stem cells paracrine proteins from three-dimensional dynamic culture system promoted wound healing in third-degree burn models. 2023;8(6): e10569. [DOI] [PMC free article] [PubMed]
- 61.Wu Y, et al. 3D bioprinting of integral ADSCs-NO hydrogel scaffolds to promote severe burn wound healing. Regen Biomater. 2021;8(3):rbab014. [DOI] [PMC free article] [PubMed]
- 62.Yang Y, et al. Exosome/antimicrobial peptide laden hydrogel wound dressings promote scarless wound healing through miR-21-5p-mediated multiple functions. Biomaterials. 2024;308: 122558. [DOI] [PubMed] [Google Scholar]
- 63.Yao W-D, et al. Hydrogel microneedle patches loaded with stem cell mitochondria-enriched microvesicles boost the chronic wound healing. ACS Nano. 2024;18(39):26733–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Zhou P, et al. A Human umbilical cord mesenchymal stem cell-conditioned medium/chitosan/collagen/β-glycerophosphate thermosensitive hydrogel promotes burn injury healing in mice. Biomed Res Int. 2019;2019:5768285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Zhou Z, et al. Acceleration of burn wound healing by micronized amniotic membrane seeded with umbilical cord-derived mesenchymal stem cells. Mater Today Bio. 2023;20: 100686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Zhu D, et al. Enhanced burn wound healing by controlled-release 3D ADMSC-derived exosome-loaded hyaluronan hydrogel. Regen Biomater. 2024;11:rbae035. [DOI] [PMC free article] [PubMed]
- 67.Viswanathan S, et al. An international society for cell and gene therapy mesenchymal stromal cells (MSC) committee perspectives on international standards organization/technical committee 276 biobanking standards for bone marrow-MSCs and umbilical cord tissue–derived MSCs for research purposes. Cytotherapy. 2023;25(8):803–7. [DOI] [PubMed] [Google Scholar]
- 68.Percie du Sert N, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMC Veterinary Res. 2020;16(1):242. [DOI] [PMC free article] [PubMed]
- 69.Radzikowska-Büchner E, et al. An overview of recent developments in the management of burn injuries. Int J Mol Sci. 2023;24(22). [DOI] [PMC free article] [PubMed]
- 70.Choi H, Choi W-S, Jeong J-O. A review of advanced hydrogel applications for tissue engineering and drug delivery systems as biomaterials. 2024;10(11):693. [DOI] [PMC free article] [PubMed]
- 71.Li Y, et al. Efficacy of stem cell therapy for burn wounds: a systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther. 2020;11(1):322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Kohlhauser M, Tuca A, Kamolz L-P. The efficacy of adipose-derived stem cells in burn injuries: a systematic review. Cell Mol Biol Lett. 2024;29(1):10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Li Y, et al. Preclinical efficacy of stem cell therapy for skin flap: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Yang Y, et al. The role of hydrogel biomaterials in the intervention of wound healing and skin regeneration via exosomes: a systematic review and meta-analysis of preclinical animal studies. Adv Wound Care (New Rochelle); 2024. [DOI] [PubMed]
- 75.Chinnici CM, et al. Mesenchymal stromal cell secretome in liver failure: perspectives on COVID-19 infection treatment. World J Gastroenterol. 2021;27(17):1905–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Cao Q, et al. Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in chronic kidney disease. Front Med (Lausanne). 2022;9: 816656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Aghayan AH, et al. Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in sepsis: a systematic review and meta-analysis of preclinical studies. Stem Cell Reviews and Reports. 2024;20(6):1480–500. [DOI] [PubMed] [Google Scholar]
- 78.Abdul Kareem N, Aijaz A, Jeschke MG. Stem cell therapy for burns: story so far. Biologics. 2021;15:379–97. [DOI] [PMC free article] [PubMed]
- 79.Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Aliniay-Sharafshadehi S, et al. Exploring the therapeutic potential of different sources of mesenchymal stem cells: a novel approach to combat burn wound infections. Front Microbiol. 2024;15:1495011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Mastrolia I, et al. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. Stem Cells Transl Med. 2019;8(11):1135–48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Berebichez-Fridman R, Montero-Olvera PR. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review. Sultan Qaboos Univ Med J. 2018;18(3):e264–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Abbas OL, et al. Comparative analysis of mesenchymal stem cells from bone marrow, adipose tissue, and dental pulp as sources of cell therapy for zone of stasis burns. J Invest Surg. 2019;32(6):477–90. [DOI] [PubMed] [Google Scholar]
- 84.Stenderup K, et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919–26. [DOI] [PubMed] [Google Scholar]
- 85.Li S, et al. Adipose-derived mesenchymal stem cells alleviate hypertrophic scar by inhibiting bioactivity and inducing apoptosis in hypertrophic scar fibroblasts. Cells. 2022;11(24). [DOI] [PMC free article] [PubMed]
- 86.Kuncorojakti S, et al. Acceleration of wound healing using adipose mesenchymal stem cell secretome hydrogel on partial-thickness cutaneous thermal burn wounds: An in vivo study IN rats. Vet World. 2024;17(7):1545–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Kim WS, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48(1):15–24. [DOI] [PubMed] [Google Scholar]
- 88.Lin CS, Lin G, Lue TF. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev. 2012;21(15):2770–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Li C, et al. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci. 2021;11(1):187. [DOI] [PMC free article] [PubMed]
- 90.Hassan N, et al. An overview of scaffolds and biomaterials for skin expansion and soft tissue regeneration: insights on zinc and magnesium as new potential key elements. 2023;15(19):3854. [DOI] [PMC free article] [PubMed]
- 91.Hu Z, et al. Biological importance of human amniotic membrane in tissue engineering and regenerative medicine. Mater Today Bio. 2023;22: 100790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Navas A, et al. Anti-inflammatory and anti-fibrotic effects of human amniotic membrane mesenchymal stem cells and their potential in corneal repair. Stem Cells Transl Med. 2018;7(12):906–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Ghasempour A, et al. Biomimetic scaffolds loaded with mesenchymal stem cells (MSCs) or MSC-derived exosomes for enhanced wound healing. Stem Cell Res Ther. 2024;15(1):406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Farjaminejad S, et al. Advances and challenges in polymer-based scaffolds for bone tissue engineering: a path towards personalized regenerative medicine. 2024;16(23):3303. [DOI] [PMC free article] [PubMed]
- 95.Olteanu G, et al. Advancements in regenerative hydrogels in skin wound treatment: a comprehensive review. Int J Mol Sci. 2024;25(7). [DOI] [PMC free article] [PubMed]
- 96.Mndlovu H, et al. A review of biomaterial degradation assessment approaches employed in the biomedical field. NPJ Mater Degradation. 2024;8(1):66.
- 97.Gounden V, Singh M. Hydrogels and wound healing: current and future prospects. 2024;10(1):43. [DOI] [PMC free article] [PubMed]
- 98.Zhu YG, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014;32(1):116–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–8. [DOI] [PubMed] [Google Scholar]
- 100.Thittamaranahalli Muguregowda H, et al. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. Plastic Aesthetic Res. 2015;2:243–9. [Google Scholar]
- 101.Honnegowda TM, et al. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. Plast Aesthet Res. 2015;2:239–42. [Google Scholar]
- 102.Yuan T, et al. Exosome derived from human adipose-derived stem cell improve wound healing quality: a systematic review and meta-analysis of preclinical animal studies. Int Wound J. 2023;20(6):2424–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv Wound Care (New Rochelle). 2015;4(3):119–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Mathew-Steiner SS, Roy S, Sen CK. Collagen in wound healing. 2021;8(5):63. [DOI] [PMC free article] [PubMed]
- 105.Larouche J, et al. Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. Adv Wound Care (New Rochelle). 2018;7(7):209–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care. 2012;25(8):349–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Schulman CI, et al. The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial. Scars Burn Heal. 2022;8:20595131211070784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Sierra-Sánchez Á, et al. Current advanced therapies based on human mesenchymal stem cells for skin diseases. Front Cell Dev Biol. 2021;9: 643125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Sensebé L, Gadelorge M, Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther. 2013;4(3):66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Zhou T, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Bauer SR. stem cell-based products in medicine: fda regulatory considerations. Handbook Stem Cells. 2004:805–14. 10.1016/B978-012436643-5/50163-2. Epub 2007 Sep 28.
- 112.Fernández-Santos ME, et al. Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome. 2022;13. [DOI] [PMC free article] [PubMed]
- 113.Golchin A. T.Z.J.S.c.r. Farahany, and reports, Biological products: cellular therapy and FDA approved products. 2019;15(2):166–75. [DOI] [PubMed]
- 114.Bauer G, Fury B. Challenges of translating a cell therapy to GMP. Int Rev Neurobiol. 2022;166:207–34. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Data S1-Search strategies.
Supplementary Data S2-Subgroup analysis.
Supplementary Data S4-Sensitivity Analysis.
Data Availability Statement
The data examined in this research can be obtained from the corresponding author upon a reasonable request.






